Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase 1 Dose-escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

NCT07458347 is registered in ClinicalTrials.gov with Kestrel Therapeutics, Inc. as lead sponsor.

NCT NCT07458347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07458347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase 1 Dose-escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
Lead sponsor
Kestrel Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 21, 2026
Completion date
May 31, 2028
Enrollment
145 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

kras-mutant colorectal cancer (crc), kras-mutant non-small cell lung cancer (nsclc), kras-mutant pancreatic ductal adenocarcinoma (pdac), other kras-mutant solid tumors